VERICEL CORPORATION Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO total compensation $11.16M; PEO compensation actually paid $169.18K; Other NEO average total compensation $2.65M.
- 2024-12-31: PEO total compensation $10.24M; PEO compensation actually paid $18.76M; Other NEO average total compensation $2.70M.
- 2023-12-31: PEO total compensation $7.06M; PEO compensation actually paid $11.00M; Other NEO average total compensation $1.92M.
- 2022-12-31: PEO total compensation $8.71M; PEO compensation actually paid $905.17K; Other NEO average total compensation $2.40M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $11.16M | $169.18K | $2.65M | $404.23K | $117.00 | $120.00 | $17.00M | Total Net Revenue $276.00M | 2026-03-19 | |
| 2024-12-31 | $10.24M | $18.76M | $2.70M | $4.25M | $178.00 | $91.00 | $10.00M | $237.00M | 2026-03-19 | |
| 2023-12-31 | $7.06M | $11.00M | $1.92M | $2.85M | $115.00 | $92.00 | -$3.00M | $198.00M | 2026-03-19 | |
| 2022-12-31 | $8.71M | $905.17K | $2.40M | $467.19K | $85.00 | $89.00 | -$17.00M | $164.00M | 2026-03-19 | |
| 2021-12-31 | $13.18M | $15.23M | $3.46M | $3.20M | $127.00 | $99.00 | -$7.00M | $156.00M | 2026-03-19 | |
| 2024-12-31 | $10.24M | $18.76M | $2.70M | $4.25M | $316.00 | $114.00 | $10.00M | Total Net Revenue $237.00M | 2025-03-20 | |
| 2023-12-31 | $7.06M | $11.00M | $1.92M | $2.85M | $205.00 | $115.00 | -$3.00M | $198.00M | 2025-03-20 | |
| 2022-12-31 | $8.71M | $905.17K | $2.40M | $467.19K | $151.00 | $111.00 | -$17.00M | $164.00M | 2025-03-20 | |
| 2021-12-31 | $13.18M | $15.23M | $3.46M | $3.20M | $226.00 | $125.00 | -$7.00M | $156.00M | 2025-03-20 | |
| 2020-12-31 | $4.41M | $10.30M | $1.16M | $1.74M | $177.00 | $126.00 | $3.00M | $124.00M | 2025-03-20 | |
| 2023-12-31 | $7.06M | $11.00M | $1.92M | $2.85M | $205.00 | $115.00 | -$3.00M | Total Net Revenue $198.00M | 2024-03-21 | |
| 2022-12-31 | $8.71M | $905.17K | $2.40M | $467.19K | $151.00 | $111.00 | -$17.00M | $164.00M | 2024-03-21 | |
| 2021-12-31 | $13.18M | $15.23M | $3.46M | $3.20M | $226.00 | $125.00 | -$7.00M | $156.00M | 2024-03-21 | |
| 2020-12-31 | $4.41M | $10.30M | $1.16M | $1.74M | $177.00 | $126.00 | $3.00M | $124.00M | 2024-03-21 | |
| 2022-12-31 | $8.71M | $905.17K | $2.40M | $467.19K | $151.00 | $111.00 | -$17.00M | $164.36M | 2023-03-23 | |
| 2021-12-31 | $13.18M | $15.23M | $3.46M | $3.20M | $226.00 | $125.00 | -$7.00M | $156.18M | 2023-03-23 | |
| 2020-12-31 | $4.41M | $10.30M | $1.16M | $1.74M | $177.00 | $126.00 | $3.00M | $124.18M | 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |